This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.
In March 2020, the FDA also approved Bristol Myers Squibb’s (BMS) own S1P receptor modulator Zeposia ( ozanimod) for the treatment of adults with relapsing forms of MS.
BMS also agreed similar conditional payments, dependent on approval, for Celgene’s multiple sclerosis therapy Zeposia (ozanimod) and another CAR-T therapy, ide-cel (idecabtagene vicleucel).
That competition paves the way for new entries, including Novartis’ ofatumumab and Bristol-Myers Squibb’s oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod which is also currently under review with
That includes an FDA decision on multiple sclerosis therapy ozanimod, which was due yesterday, and a verdict due by 4 April for Reblozyl (luspatercept) as a second-line therapy for anaemia
Bristol-Myers Squibb may also possess a potential rival, as it is due for an FDA decision on its MS drug ozanimod soon, following a series of delays due to the
BMS share price up by 3% on the back of results
More from news
Approximately 3 fully matching, plus 22 partially matching documents found.
The FDA accepted the filing for Ozanimod in June 2019 with a target PDUFA date of 25 March 2020. ... As with ozanimod, if OMB-157 is approved it will find a very crowded multiple sclerosis market with some very notable competitors, particularly in the
treatment ozanimod and myelodysplastic syndromes/beta thalassaemia candidate luspatercept – to deliver on their potential.
Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...